# Recent advances in the study of Conbercept for diabetic macular edema

## TL;DR

This paper reviews recent developments in using Conbercept, a Chinese-made drug, to treat diabetic macular edema, a leading cause of blindness in diabetic patients.

## Contribution

The paper provides a systematic review of Conbercept's mechanism and recent clinical advancements in treating DME.

## Key findings

- Conbercept shows significant efficacy in treating diabetic macular edema.
- The paper compares Conbercept with other anti-VEGF therapies and highlights its advantages.
- Current research limitations and future directions for Conbercept are discussed.

## Abstract

Diabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant efficacy in the treatment of DME in recent years. This systematic review explores the mechanism of action and latest research advancements of Conbercept in DME treatment, integrating clinical trial data and comparisons with other anti-VEGF therapies. It further discusses existing limitations in current research and proposes future research directions.